Liven Pharma to Raise Rs. 200 Million Through Rights Issue

Liven Pharma Limited said it will raise Rs. 200 million via a rights issue to strengthen its financial position and fund expansion. The company disclosed to the Pakistan Stock Exchange that it will issue 20 million ordinary shares at Rs. 10 each, representing about 21.5% of its paid-up capital. Shareholders will receive 21.496 rights shares for every 100 ordinary shares held. Liven Pharma said proceeds will be used to support working capital, capital expenditures, and new investments, including a Dry Powder Injectables division, vehicle procurement, and costs related to Drug Regulatory Authority of Pakistan registration and licensing. The company noted the issue price is set at face value, in line with prevailing market practice, and said substantial shareholders and directors have confirmed participation. According to the disclosure, the rights issue is expected to improve profitability and shareholder returns while posing minimal investment risk, as the price is below the current market level. The principal activity of the company is the manufacturing of pharmaceuticals and allied products.